Amneal Pharmaceuticals Inc (NYSE:AMRX) revealed on Friday the receipt of US FDA approval for the generic version of Isuprel Injection (isoproterenol hydrochloride) USP in 0.2 mg/ml and 1 mg/5 ml(0.2 mg/ml) Single-Dose Vials.

Effective immediately, the company has initiated commercialisation activities for Isuprel Injection (isoproterenol hydrochloride) USP in 0.2 mg/ml and 1 mg/5 ml(0.2 mg/ml) Single-Dose Vials. Isoprenaline, or isoproterenol, is a medication used for the treatment of bradycardia (slow heart rate), heart block and rarely for asthma.

According to IQVIA, US market annual sales for the 12 months ended August 2018 for Isoproterenol Hydrochloride Injection USP in 0.2 mg/ml and 1 mg/5 ml(0.2 mg/ml) Single-Dose Vials is estimated to be approximately USD158m.

Headquartered in Bridgewater, NJ, the pharmaceutical company is focused on developing, manufacturing and distributing generic, brand and biosimilar products.